Search

Displaying results 3641 - 3650 of 5898 in total
  1. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    (6-9) that is important for binding to the known melanocortin receptors. … It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.

  2. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    This is a novel therapeutic approach to treat kidney inflammation. … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.

  3. Drug

    Tyrothricin

    go.drugbank.com/drugs/DB13503
    ApprovedWithdrawn

    Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do

  4. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

  5. Drug

    Anumigilimab

    go.drugbank.com/drugs/DB16359
    Investigational

    CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques.

  6. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  7. Drug

    Anti-SARS-CoV-2 immunoglobulin

    go.drugbank.com/drugs/DB16360
    Investigational

    Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies.

    Synonyms: Hyperimmune immunoglobulin to SARS-CoV-2
  8. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.

  9. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.

  10. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.